[An Overview and Interpretation of Important Clinical Studies 
on Non-small Cell Lung Cancer in 2021]

Area of Science:

• Oncology
• Pulmonology
• Clinical Research

Background:

• Despite the ongoing COVID-19 pandemic in 2021, clinical research for non-small cell lung cancer (NSCLC) continued.
• Significant improvements in overall survival and quality of life have been observed in NSCLC patients due to treatment advancements.

Purpose of the Study:

• To review pivotal studies and research advancements in non-small cell lung cancer (NSCLC) treatment from 2021.
• To highlight therapies expected to alter clinical practice and improve patient outcomes in NSCLC.

Main Methods:

• Review of important clinical studies and research advances in NSCLC treatment published in 2021.
• Analysis of new treatment modalities and therapeutic agents for resectable, locally advanced, and advanced NSCLC.

Main Results:

• Targeted therapy and immunotherapy have revolutionized postoperative adjuvant therapy for resectable NSCLC, setting new treatment standards.
• New treatment modalities and agents for locally advanced and advanced NSCLC offer expanded clinical options.
• These advancements suggest a future where non-small cell lung cancer may become a chronic condition.

Conclusions:

• Recent research in targeted therapy and immunotherapy has significantly improved outcomes for non-small cell lung cancer (NSCLC) patients.
• The evolving treatment landscape for NSCLC, including advances in adjuvant and systemic therapies, is paving the way for better long-term management.
• Future clinical practice for NSCLC will likely incorporate these novel approaches, potentially leading to a more chronic disease trajectory.